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ffectiveness of herpes zoster vaccine on recurrent herpes
oster among an immunocompetent elderly population
.F. Tseng ∗, M. Chi, N. Smith, S.M. Marcy, L. Sy, S. Jacobsen
Kaiser Permenante, Pasadena, CA, USA
Background: Since 2006 when the zoster vaccine was ﬁrst
icensed, one of the most commonly asked questions by patients
nd clinicians has been “Should a patient with a history of herpes
oster (HZ) receive the vaccine to prevent another episode?”. The
eneﬁt of vaccinating immunocompetent patients who have had
hingles has not been examined. The study assessed the association
etween vaccination and the incidence of herpes zoster recurrence
mong personswith a recent episode of clinically diagnosed herpes
oster.
Methods: This is a matched cohort study in Kaiser Permanente
outhern California. Study populations were immunocompetent
lderly≥ 60 years oldwith a recent episode of herpes zoster. Poten-
ial recurrent HZ cases were identiﬁed electronically by ICD-9 code
f 053.xx from outpatient, emergency, and inpatient ﬁles. Med-
cal records of electronically identiﬁed cases were retrieved and
eviewed masked to vaccination status by an infectious disease
pecialist using pre-speciﬁed review criteria. Incidence of recur-
ent herpes zoster was compared between the vaccinated and the
nvaccinated matched cohorts. The hazard ratio associated with
accination was adjusted for a propensity score that accounted for
otential confounders.
Results: There were total 1,036 vaccinated and 5,180 unvacci-
ated members included. Based on the clinically conﬁrmed cases,
he incidence of recurrent HZ among age <70 cohort was 0.99 (95%
I, 0.02-5.54) and 2.20 (95% CI, 1.10-3.93) per 1,000 person-years
n the vaccinated and the unvaccinated cohort, respectively. The
djusted hazard ratio comparing the vaccinated and the unvacci-
ated population was 0.39 (95% CI, 0.05- 4.45). It was 1.05 (95% CI,
.30-3.69) among the age ≥70 cohorts.
Conclusion: The short term risk of HZ recurrence following a
ecent initial episode is fairly lowamong immunocompetentadults,
egardless of vaccination status. While there was a trend towards
ower rates in individuals vaccinatedwith zoster vaccine, especially
n thoseyounger than70yearsold, the rarityof outcome limitedour
bility tomakedeﬁnitive statementsabout theeffectof vaccination.
egardless, such a low risk suggests that one should evaluate the
ecessity of immediately vaccinating immunocompetent patientsfectious Diseases 16S (2012) e158–e316
with a recent HZ episode, especially given the periodic shortages of
zoster vaccine.
http://dx.doi.org/10.1016/j.ijid.2012.05.1017
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to 17 year-old children
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1 University of Tampere Medical School, Tampere, Finland
2 University of Siena, Sienna, Italy
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Background: Ongoing A/H5N1 viral transmission in SouthEast
Asia poses a pandemic threat. Effective vaccines must provide
cross-reactive antibody responses to a future exposure as the
virus is evolving. We report responses to a booster does of
MF59®-adjuvanted A/H5N1 vaccine (Aﬂunov®, Novartis Vaccines)
in children who were primed one year earlier.
Methods: In this randomized, observer-blind study, conducted
at the University of Tampere Medical School, Finland, cohorts of
healthy children aged 6-35 months (n=117), 3-8 years (n =84),
and 9-17 years (n =82) received vaccine containing 7.5g of
A/H5N1/Vietnam/1194/2004 (clade 1) inﬂuenza antigen and a
standard dose of MF59 oil-in-water adjuvant in a two-dose
priming series and, one year later, as a single booster dose. Cross-
reactive antibody responses against heterologous A/H5N1 strains,
A/Anhui/1/2005 (subclade2.3.4) andA/Indonesia/5/2005 (subclade
2.1.3.2) were analysed by microneutralization assay (MN) three
weeks (Day 43) and one year (Day 382) after primary immuniza-
tion, and three weeks after booster vaccination (Day 403).
Results: 99-100% of subjects achived MN titers ≥ 80 to all three
strains after booster vaccination. Pre-booster anbd booster dose
geometric mean titers (GMT) were inversely related to age, with
the highest titers seen in 6-35 month-olds. GMT responses were
higher to the heterologous Anhui 2.3.4 subclade virus than to the
homologous Vietnam subclade 1.1 virus.
Conclusion: Booster immunization with MF59-adjuvanted
A/H5N1 vaccine one year after priming led to putatively protec-
tive levels of MN antibodies to both homologous and heterologous
viruses. Pre-pandemic priming with MF59-adjuvanted A/H5N1
vaccine could facilitate an emergencypublic healthprogram,with a
single dose of antigen-sparing vaccine providing a broadly reactive
response.
http://dx.doi.org/10.1016/j.ijid.2012.05.1018
